Titre
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Bures, R.
Auteure/Auteur
Gaitan, A.
Auteure/Auteur
Zhu, T.
Auteure/Auteur
Graziosi, C.
Auteure/Auteur
McGrath, K. M.
Auteure/Auteur
Tartaglia, J.
Auteure/Auteur
Caudrelier, P.
Auteure/Auteur
El Habib, R.
Auteure/Auteur
Klein, M.
Auteure/Auteur
Lazzarin, A.
Auteure/Auteur
Stablein, D. M.
Auteure/Auteur
Deers, M.
Auteure/Auteur
Corey, L.
Auteure/Auteur
Greenberg, M. L.
Auteure/Auteur
Schwartz, D. H.
Auteure/Auteur
Montefiori, D. C.
Auteure/Auteur
Liens vers les personnes
cgrazios
Liens vers les unités
ISSN
0889-2229
Statut éditorial
Publié
Date de publication
2000-12
Volume
16
Numéro
18
Première page
2019
Dernière page/numéro d’article
35
Notes
Clinical Trial
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S. --- Old month value: Dec 10
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S. --- Old month value: Dec 10
Résumé
Antibodies generated by candidate HIV-1 vaccines in a phase I clinical trial were assessed for neutralizing activity with a panel of eight well-characterized, genetically diverse clade B primary isolates having an R5 phenotype. The vaccines consisted of one of three different recombinant canarypox vectors expressing membrane-anchored HIV-1(MN)gp120 (ALVAC vCP205, vCP1433, and vCP1452) followed by boosting with a soluble gp160 hybrid consisting of MNgp120 and the majority of gp41 from strain IIIB. Serum samples from a subset of volunteers in each arm of the trial, containing moderate to high titers of neutralizing antibodies to HIV-1 MN, were analyzed. Competition assays with peptides revealed that the majority of neutralizing activity was specific for the MN-V3 loop. Despite MN-specific neutralization titers that sometimes exceeded 1:500, no neutralization of primary isolates was detected and, in some cases, mild infection enhancement was observed. In addition, little or no neutralization of the HIV-1 IIIB heterologous T cell line-adapted strain of virus was detected. These results reinforce the notion that monovalent HIV-1 ENV is a poor immunogen for generating cross-reactive neutralizing antibodies.
Sujets
PID Serval
serval:BIB_BD9982B15939
PMID
Date de création
2008-01-25T13:58:22.102Z
Date de création dans IRIS
2025-05-20T23:17:02Z